Security Snapshot

Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI) Institutional Ownership

Q: What is CUSIP 48576U106?

CUSIP 48576U106 is the security identifier used in SEC filing datasets for KPTI - Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share.

Q: Who owns KPTI - Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share based on 13F filings?

Open this security page to review the newest available 13F ownership history, top reported holders, and period-by-period changes.

CUSIP: 48576U106

13F Institutional Holders and Ownership History from Q1 2014 to Q4 2025

Latest Period

Q4 2025

Institutions Reporting

Shares (Excl. Options)

Price

$0.60

Save this security page for your next review

Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.

Create free account and return here Sign in and return here Review latest holder period

Type / Class: Equity / Common Stock, par value $0.0001 per share
Symbol: KPTI on Nasdaq
Shares outstanding: 22,242,217
Price per share: $0.60
All holders as of 31 Dec 2025: Q4 2025
Total 13F shares: 0
Total reported value: $0
Share change: -27,985
Value change: -$183,022
Number of holders: 0
Price from insider filings: $0.60

Reported Shares, Excluding Options vs Price

Reported Value, Excluding Options

Total Investors

Quick Takeaways

KPTI - Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share is tracked under CUSIP 48576U106.
0 institutions reported positions in Q4 2025.
4 significant owners is listed from Schedule 13D/13G reporting.

What Changed

Holder count moved from 1 to 0 between Q3 2025 and Q4 2025.
Reported value moved from $183,022 to $0.

Why This Matters

You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.

Source Evidence

Source: SEC Form 13F

Latest holder context comes from 0 institutions filings for Q4 2025.

Open SEC Evidence

Investment Quick Answers

What is CUSIP 48576U106?
CUSIP 48576U106 identifies KPTI - Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share in SEC 13F datasets.

Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.

Next ownership checks

Use the next link that matches the question you still need to answer about this security.

Latest 13F filings when you want to inspect fresh institutional portfolio moves.
Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
All institutional ownership pages to compare this security with other holder-history pages.

Recent Quarterly Holder Reports

Open recent reporting periods for CUSIP 48576U106:

Q4 2025 (0 holders) Q3 2025 (1 holder) Q2 2025 (1 holder) Q1 2025 (2 holders) Q4 2024 (87 holders) Q3 2024 (90 holders) Q2 2024 (114 holders) Q1 2024 (111 holders) Q4 2023 (118 holders) Q3 2023 (117 holders)

Significant Owners of Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI) based on Schedule 13D/G filings

Filer	Ownership	Holdings Value	Nb Shares	Reporting Name	Report Period
Adage Capital Management, L.P.	5.2%	$24,500,946	6,551,055	Adage Capital Management, L.P.	31 Dec 2024
RA CAPITAL MANAGEMENT, L.P.	9.9%	$1,247,348	2,078,913	RA Capital Management, L.P.	26 Mar 2026
Commodore Capital LP	9.9%	$1,170,000	1,950,000	Commodore Capital LP	26 Mar 2026
INTEGRATED CORE STRATEGIES (US) LLC	2.3%	$306,943	511,571	Millennium Management LLC	31 Mar 2026

As of 31 Dec 2025, 0 institutional investors reported holding 0 shares of Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI). This represents 0% of the company’s total 22,242,217 outstanding shares.

Institutional Holders of Karyopharm Therapeutics Inc. - Common Stock, par value $0.0001 per share (KPTI) across Reporting Periods

Period	Reported Shares, Excl. Options	Value, Excl. Options	Value Change	Puts Notional Value	Calls Notional Value	Price (Median)	Investors
2025 Q4	0	$0	-$183,022			$0.60	0
2025 Q3	27,985	$183,022				$6.54	1
2025 Q2	27,985	$120,615	-$1,211,880			$4.31	1
2025 Q1	352,017	$1,316,544	-$55,318,808	$0	$0	$3.74	2
2024 Q4	60,912,948	$41,204,113	-$289,373	$45,661	$100,073	$0.68	87
2024 Q3	59,278,240	$49,194,051	-$6,331,563	$65,911	$214,472	$0.83	90
2024 Q2	67,556,361	$58,626,062	-$7,639,125	$86,044	$434,749	$0.87	114
2024 Q1	74,702,822	$112,801,347	+$3,989,777	$264,401	$226,198	$1.51	111
2023 Q4	73,344,053	$63,441,322	-$4,574,345	$6,401	$369,993	$0.86	118
2023 Q3	76,219,647	$102,134,785	-$10,719,386	$161,738	$562,666	$1.34	117
2023 Q2	80,450,419	$144,011,333	-$18,617,679	$182,324	$434,804	$1.79	133
2023 Q1	87,557,859	$340,123,767	-$32,799,976	$411,173	$935,965	$3.89	128
2022 Q4	98,414,676	$334,456,268	+$99,576,581	$969,680	$694,960	$3.40	152
2022 Q3	66,862,684	$365,052,989	-$620,374	$1,757,000	$1,812,000	$5.46	142
2022 Q2	67,139,765	$302,788,902	-$7,006,335	$1,394,000	$2,312,000	$4.51	144
2022 Q1	68,286,528	$501,776,522	+$108,241,216	$3,440,000	$7,662,700	$7.37	134
2021 Q4	54,170,305	$347,414,468	-$3,383,122	$8,726,000	$2,551,000	$6.43	138
2021 Q3	57,408,855	$334,396,841	-$25,823,482	$7,568,000	$1,512,000	$5.82	130
2021 Q2	58,982,285	$608,669,781	-$13,934,484	$13,371,000	$3,229,000	$10.32	147
2021 Q1	59,160,795	$622,242,344	-$49,072,460	$3,107,000	$1,256,000	$10.52	163
2020 Q4	63,829,194	$988,058,899	-$54,468,075	$6,365,000	$9,039,000	$15.48	165
2020 Q3	65,150,667	$951,174,601	-$110,130,293	$4,017,000	$4,903,000	$14.60	155
2020 Q2	69,738,739	$1,320,807,090	+$45,201,421	$5,134,000	$10,565,000	$18.94	155
2020 Q1	67,992,711	$1,305,743,291	+$217,084,502	$19,240,000	$14,453,000	$19.21	135
2019 Q4	58,955,103	$1,130,098,649	-$54,693,103	$13,388,000	$10,361,000	$19.17	146
2019 Q3	58,481,490	$562,607,545	+$83,519,427	$2,909,000	$2,968,000	$9.62	105
2019 Q2	51,164,991	$306,457,439	+$3,407,218	$577,000	$4,457,000	$5.99	102
2019 Q1	51,219,533	$299,625,643	-$24,705,356	$1,158,000	$2,240,000	$5.84	101
2018 Q4	51,412,770	$481,695,108	+$75,184,187	$752,000	$470,000	$9.37	116
2018 Q3	43,286,107	$737,162,850	-$818,029	$3,435,000	$854,000	$17.03	117
2018 Q2	43,354,403	$736,589,579	+$217,013,290	$479,000	$440,000	$16.99	108
2018 Q1	30,891,981	$414,567,351	+$174,090	$2,687,000	$2,391,000	$13.42	87
2017 Q4	31,007,107	$297,662,901	+$20,343,235	$242,000	$771,000	$9.60	88
2017 Q3	28,741,389	$315,542,785	+$10,686,137	$116,000	$679,000	$10.98	74
2017 Q2	27,780,067	$251,407,245	+$6,202,394	$780,000	$734,000	$9.05	71
2017 Q1	26,846,913	$344,713,183	+$45,322,035	$691,000	$871,000	$12.84	79
2016 Q4	25,467,293	$239,390,343	+$21,237,489	$0	$828,000	$9.40	85
2016 Q3	23,180,959	$225,551,522	+$31,499,955	$68,000	$542,000	$9.73	77
2016 Q2	20,044,622	$134,499,864	-$8,387,552	$82,000	$172,000	$6.71	73
2016 Q1	21,165,907	$188,770,460	-$5,334,988	$173,000	$470,000	$8.92	76
2015 Q4	21,560,134	$285,674,019	-$24,016,754	$2,072,000	$2,725,000	$13.25	86
2015 Q3	23,545,780	$247,934,145	-$6,616,775	$2,161,000	$9,090,000	$10.53	87
2015 Q2	22,391,611	$609,266,884	+$40,371,623	$3,521,000	$2,623,000	$27.21	88
2015 Q1	20,794,207	$636,290,225	+$53,545,677	$3,808,000	$2,615,000	$30.61	85
2014 Q4	18,742,387	$701,526,058	+$50,285,065	$1,449,000	$1,093,000	$37.43	81
2014 Q3	16,817,880	$587,612,971	+$52,881,540	$1,799,000	$1,730,000	$34.94	70
2014 Q2	15,117,534	$703,718,591	+$235,116,570			$46.55	78
2014 Q1	10,072,951	$310,923,978	+$33,552,565			$30.89	59